Tarraga-Lopez, Pedro J.; Celada-Rodriguez, Angel; … - In: PharmacoEconomics 23 (2005) 3, pp. 275-287
Background: Cardiovascular disease is one of the leading causes of death and it has been shown that primary prevention with the HMG-CoA reductase inhibitor (statin) lipid-lowering drugs can reduce cardiovascular events. Acquisition costs vary between statins and this may be an important...